Get Citius Pharmaceuticals Inc (CTXR.A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments. Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology. Citius Pharmaceuticals (NASDAQ: CTXR) advances oncology asset, paving way for spin out of advanced T-cell lymphoma treatment. CTXR Company Profile Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Stay up-to-date on Citius Pharmaceuticals, Inc. Common Stock (CTXR) news with the latest updates, breaking headlines, news articles, and more from around.
Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company, engages in the development and commercialization of critical care products. News for Citius Pharmaceuticals Inc Registered Shs Why Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today? Citius Pharmaceuticals Executes Definitive. Citius Pharmaceuticals Inc CTXR:NASDAQ · Open · Day High · Day Low · Prev Close · 52 Week High · 52 Week High Date04/02/24 · 52 Week. Citius Pharmaceuticals Inc. NASDAQ: CTXR is a pharmaceutical company focused on developing and commercializing critical care products. Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology. Stock Quote: Nasdaq: CTXR ; Day's Open. $ Closing Price. $ ; Intraday Low. $ Intraday High. $ ; Volume. , Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc. Citius Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CTXR. The last closing price for Citius Pharmaceuticals. Citius Pharmaceuticals Inc. ; Next Fiscal Year Estimate, ; Median PE on Next FY Estimate, N/A ; High, $ ; Median, $ ; Low, $ Citius Pharmaceuticals Inc. (Nasdaq: CTXR) is a specialty biopharmaceutical company dedicated to the development and commercialization of first-in-class. Citius Pharmaceuticals (NASDAQ: CTXR) advances oncology asset, paving way for spin out of advanced T-cell lymphoma treatment.
Get Citius Pharmaceuticals Inc (CTXR.A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments. (Nasdaq: CTXR) is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a. CTXR Citius Pharmaceuticals Inc. 22, $ $ (%). Today. Watchers, 22, Wk Low, $ Wk High, $ Market Cap, $M. On Friday 09/13/ the closing price of the Citius Pharmaceuticals Inc Registered Shs share was $ on BTT. Compared to the opening price on Friday 09/13/. In the current month, CTXR has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CTXR average Analyst price target in the past 3 months is $ CTXR stock results show that Citius Pharma met analyst estimates for earnings per share the third quarter of News Image. 22 days ago - BusinessInsider. Citius Pharmaceuticals Inc (NASDAQ:CTXR) secures FDA approval on Thursday for Lymphir (denileukin diftitox-cxdl) to treat relapsed or refractory cutaneous T-. Discover real-time Citius Pharmaceuticals, Inc. Common Stock (CTXR) stock prices, quotes, historical data, news, and Insights for informed trading and. Get the latest Citius Pharmaceuticals Inc (CTXR) real-time quote, historical performance, charts, and other financial information to help you make more.
HC Wainwright & Co. analyst Vernon Bernardino reiterates Citius Pharma (NASDAQ:CTXR) with a Buy and maintains $4 price target. BenzingaMay 31 ET. Shares of Citius jump 18% on new data for experimental lymphoma drug. Shares of Citius Pharmaceuticals Inc. were up % in premarket trading on Wednesday. Based on 2 Wall Street analysts offering 12 month price targets for Citius Pharmaceuticals in the last 3 months. The average price target is $ with a high. Citius Pharmaceuticals, Inc. reports fiscal third quarter financial results and provides business update. The average one-year price target for Citius Pharmaceuticals, Inc. is $ The forecasts range from a low of $ to a high of $ A stock's price target.
3 Simple Reasons Why I Bought More CELH Stock (no, Pepsi won't buy them out)
Find the latest Citius Pharmaceuticals Inc. (CTXR) stock quote, history, news and other vital information to help you with your stock trading and investing. Citius Pharmaceuticals Inc. ; Volume, M ; Market Value, $M ; Shares Outstanding, M ; EPS (TTM), -$ ; P/E Ratio (TTM), N/A. See charts, data and financials for Citius Pharmaceuticals Inc CTXR. The Citius Pharmaceuticals Inc (CTXR) share price is expected to increase by % over the next year. This is based on calculating the average month share. Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Citius Pharmaceuticals to receive million shares of. Citius Pharmaceuticals stock was originally listed at a price of $ in Jul 6, If you had invested in Citius Pharmaceuticals stock at $, your return.